Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability

Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability

Lung cancer has the highest mortality rate among all cancer types, resulting in over 1.8 million deaths annually. Immunotherapy utilizing immune checkpoint inhibitors (ICIs) has revolutionized the treatment of non-small cell lung cancer (NSCLC). ICIs, predominantly monoclonal antibodies, modulate co...

Full description

Bibliographic Details
Main Authors: Katiane Tostes, Aléxia Polo Siqueira, Rui Manuel Reis, Leticia Ferro Leal, Lidia Maria Rebolho Batista Arantes
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:International Journal of Molecular Sciences
Subjects:
immunotherapy
immune checkpoint inhibitors
non-small cell lung cancer
PD-L1
predictive biomarkers
Online Access:https://www.mdpi.com/1422-0067/24/15/11887

Internet

https://www.mdpi.com/1422-0067/24/15/11887

Similar Items